HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. [electronic resource]
Producer: 20030725Description: 111-20 p. digitalISSN:- 1359-6535
- Alkynes
- Anti-HIV Agents -- therapeutic use
- Antiretroviral Therapy, Highly Active
- Benzoxazines
- Carbamates
- Cohort Studies
- Cyclopropanes
- Dideoxynucleosides -- therapeutic use
- Drug Resistance, Viral -- genetics
- Drug Therapy, Combination
- Furans
- Genotype
- HIV Infections -- drug therapy
- HIV Protease -- genetics
- HIV Reverse Transcriptase -- genetics
- HIV-1 -- drug effects
- Humans
- Mutation
- Oxazines -- therapeutic use
- Salvage Therapy
- Sulfonamides -- therapeutic use
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.